Search Results - "Gandhi, Mitul"

Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies by Xu, Linlin, Shadman, Mazyar, Flinn, Ian W, Levy, Moshe Y, Porter, Ryan, Burke, John M, Zafar, Syed F, Cultrera, Jennifer L, Misleh, Jamal, Kingsley, Edwin C, Yimer, Habte A, Freeman, Benjamin, Chaudhry, Arvind, Tumula, Praveen K, Gandhi, Mitul D, Crescenzo, Rocco, By, Kunthel, Cohen, Aileen, Chen, Dih-Yih, Idoine, Adam, Manda, Sudhir, Sharman, Jeff P, Ramakrishnan, Vanitha

Get full text

Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study by Shadman, Mazyar, Flinn, Ian W, Levy, Moshe Y, Porter, Ryan F, Burke, John M, Zafar, Syed F, Misleh, Jamal, Kingsley, Edwin C, Yimer, Habte A, Freeman, Benjamin, Rao, Subramanya S, Chaudhry, Arvind, Tumula, Praveen K, Gandhi, Mitul D, Manda, Sudhir, Chen, Dih-Yih, By, Kunthel, Xu, Linlin, Liu, Ye, Crescenzo, Rocco, Idoine, Adam, Zhang, Xiaoping, Cohen, Aileen, Huang, Jane, Sharman, Jeff P

“…We hypothesised that zanubrutinib, a highly selective next-generation Bruton tyrosine kinase (BTK) inhibitor, would be a safe and active treatment for patients…”
Get full text

A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma by Paul, Barry, Liedtke, Michaela, Khouri, Jack, Rifkin, Robert, Gandhi, Mitul D, Kin, Andrew, Levy, Moshe Y, Silbermann, Rebecca, Cottini, Francesca, Sborov, Douglas W, Sandhu, Irwindeep, Villarreal, Lyssa, Murphy, Michael, Gu, Lin, Chen, Ann, Rajakumaraswamy, Nishanthan, Usmani, Saad Z

“…Magrolimab is a monoclonal antibody that blocks CD47, a ‘do not eat me’ signal overexpressed on tumor cells. CD47 is overexpressed in multiple myeloma (MM),…”
Get full text

Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event by Gandhi, Mitul D., Evens, Andrew M., Fenske, Timothy S., Hamlin, Paul, Coiffier, Bertrand, Engert, Andreas, Moskowitz, Alison J., Ghosh, Nilanjan, Petrich, Adam M., Lomasney, Jon, Chadburn, Amy, Wood, Gary S., Salva, Katrin, Nardone, Beatrice, Trifilio, Steven M., Raisch, Dennis W., West, Dennis P., Gordon, Leo I., Winter, Jane N.

Get full text

Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib by Gandhi, Mitul D, Agulnik, Mark

“…Squamous-cell cancer of the head and neck is a heterogeneous malignancy with treatment predicated on a multimodality therapy involving surgery, chemotherapy,…”
Get full text

Predicting benefit from imatinib: are we close? by Gandhi, Mitul D., Kaklamani, Virginia G.

Get full text

P1064: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE FOR ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: UPDATED EFFICACY AND SAFETY RESULTS FROM THE SINGLE ARM PHASE 2 STUDY by Yasenchak, Chris, Flinn, Ian W., Melear, Jason, Ramchandren, Rod, Friedman, Judah, Burke, John M., Linhares, Yuliya, Gonzales, Paul, Raval, Mihir, Chintapatla, Rangaswamy, Feldman, Tatyana A., Yimer, Habte, Islas‐Ohlmayer, Miguel, Dean, Asad, Rana, Vishal, Gandhi, Mitul D., Renshaw, John, Ho, Linda, Fanale, Michelle, Guo, Wenchuan, Ju Lee, Hun

Get full text

Association of implantable defibrillator therapy risk with body mass index in systolic heart failure by Gandhi, Mitul, MD, Koelling, Todd M., MD, Pelosi, Frank, MD, Patel, Shaun P., MD, Wojcik, Brandon M., MD, Horwood, Laura E., MS, NP, Wu, Audrey H., MD, MPH

“…Abstract Objectives To determine whether risk for implantable cardioverter-defibrillator (ICD) therapy varies by body mass index (BMI) in systolic heart…”
Get full text

Brentuximab vedotin in patients with relapsed HIV-related lymphoma by Gandhi, Mitul, Petrich, Adam

“…Lymphoma is a well-recognized complication in patients infected with HIV. Although its incidence has declined since the advent of antiretroviral therapy, it…”
Get more information

Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7) by Hess, Brian T., Solh, Melhem M., Gandhi, Mitul, Wang, Ying, Qin, Yajuan, Yu, Eric, Zinzani, Pier Luigi, Collins, Graham P.

“…TPS7581 Background: Combining agents with different mechanisms of action may enhance treatment (Tx) efficacy in patients (pts) with relapsed/refractory (R/R)…”
Get full text

A Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination with Other Anticancer Agents in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (LOTIS-7) by Hess, Brian T., Collins, Graham P., Solh, Melhem, Gandhi, Mitul, Wang, Ying, Qin, Yajuan, Yu, Eric, Zinzani, Pier Luigi

Get full text

Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5 by Hamadani, Mehdi, Linhares, Yuliya, Gandhi, Mitul, Chung, Michael, Adamis, Helena, Ungar, David, Carlo-Stella, Carmelo

“…Abstract only TPS7574 Background: Patients (pts) with DLBCL for whom frontline therapy is unsuccessful and who are ineligible for autologous stem cell…”
Get full text

Covalent-103: A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study of Bmf-500, an Oral Covalent FLT3 Inhibitor, in Adults with Acute Leukemia (AL) by Rotta, Marcello, Ravandi, Farhad, Gandhi, Mitul, Koller, Paul B., Schiller, Gary J., Follit, Courtney, Vimal, Mona, Morris, Stephan W., Mourya, Sanchita, Butler, Thomas, Wang, Eunice S.

“…Background: FLT3 mutations occur in 25-35% of patients with AML and are associated with poor prognosis. FLT3 mutations are most frequently the result of an…”
Get full text

NHL Patients and Nurses in the US Prefer Subcutaneous Rituximab Injection Versus Intravenous Rituximab Infusion: A Real-World Study by Gandhi, Mitul D, Shapouri, Sheila, Ravelo, Arliene, Sudharshan, Lavanya, Beeks, April, Dawson, Keith L

“…Introduction: In 2017, the US FDA granted approval of a subcutaneous (SC) injection form of rituximab as an alternative means of administration for patients…”
Get full text

Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma by Linhares, Yuliya, Gandhi, Mitul D, Chung, Michael, Adeleye, Jennifer, Ungar, David, Hamadani, Mehdi

“…Introduction: Patients with diffuse large B-cell lymphoma (DLBCL) who fail immunochemotherapy (IC) and are unsuitable for autologous stem cell transplantation…”
Get full text

ABCL-134 Phase Ib Open-Label Study of Loncastuximab Tesirine in Combination With Other Anticancer Agents in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (LOTIS-7) by Hess, Brian, Solh, Melhem, Gandhi, Mitul, Wang, Ying, Qin, Yajuan, Zinzani, Pier Luigi, Collins, Graham

“…Combining agents with different mechanisms of action may enhance treatment (Tx) efficacy in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin…”
Get full text

POSTER: ABCL-134 Phase Ib Open-Label Study of Loncastuximab Tesirine in Combination With Other Anticancer Agents in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (LOTIS-7) by Hess, Brian, Solh, Melhem, Gandhi, Mitul, Wang, Ying, Qin, Yajuan, Zinzani, Pier Luigi, Collins, Graham

Get full text

Nurse Treatment Preferences Survey for Intravenous Rituximab Infusion Versus Subcutaneous Rituximab Injection: A Real-World Study by Gandhi, Mitul D., Shapouri, Sheila, Ravelo, Arliene, Sudharshan, Lavanya, Clark, Jamyia, Dawson, Keith L.

“…Introduction: The 2017 US FDA approval of a subcutaneous (SC) injection form of rituximab made available an alternative means of administering rituximab for…”
Get full text

Phase 3 randomized study of loncastuximab tesirine in combination with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL (LOTIS-5) by Hamadani, Mehdi, Linhares, Yuliya, Gandhi, Mitul, Chung, Michael, Adamis, Helena, Ungar, David, Carlo-Stella, Carmelo, Kingsley, Ed, Depaus, Julien, Snauwaert, Sylvia, Kwiatek, Michal, López-Jiménez, Javier

“…TPS7591 Background: Patients (pts) with refractory or relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes with standard treatment…”
Get full text

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study by Paul, Barry, Minarík, Jirí, Cottini, Francesca, Gasparetto, Cristina, Khouri, Jack, Gandhi, Mitul, Hillengass, Jens, Levy, Moshe, Liedtke, Michaela, Manda, Sudhir, Sandhu, Irwindeep, Sborov, Douglas, Spicka, Ivan, Usmani, Saad Z, Gu, Lin, Robeson, Michelle, Murphy, Michael, Renard, Camille, Chen, Christine, Pour, Luděk

“…Background Outcomes remain poor for patients (pts) with RRMM; thus, novel combinations incorporating standard-of-care (SOC) regimens with new drugs possessing…”
Get full text